CRESEMBA receives seven years and six months of US market exclusivity for these pediatric indications
It is the first autotaxin inhibitor to be investigated in cancer patients
Zydus Lifesciences receives EIR report from USFDA for API Ahmedabad facility
The company will provide comprehensive response to USFDA for the observations
The product combines proven efficacy of Doxylamine succinate 20 mg and Pyridoxine hydrochloride 20 mg in an Extended Release formulation
These approvals mark significant progress for Venus Remedies in expanding its market presence
The inspection was concluded with few procedural observations
The plan is to set up an ultramodern Solvent Recovery Plant for third party purposes
The disbursement will bolster the company's manufactun'ng capabjljties and foster product diversification, including complex generics
Nectar Lifesciences has clarified that the company has no relation/connection/ association or link of any nature with the Nectar Herbs and Drugs
Subscribe To Our Newsletter & Stay Updated
